Michael Byrnes ’00 has been appointed chief financial officer for FORE Biotherapeutics. With over 20 years of experience in the biotechnology industry, Byrnes has navigated all development phases from early research to preparing for market launch. He has also raised over $300 million in equity and debt capital and been involved in mergers and acquisitions worth nearly $4 billion.